Undisclosed · Growth/Late · E-commerce, Healthtech · Paris, France
Paris-based Doctolib, which provides scheduling and practice software for healthcare professionals and patients, has announced a planned minority investment from NVIDIA. The company says the investment will help it recruit AI specialists and accelerate development of its healthcare AI tools.
The parties describe the transaction as planned or agreed. Neither has disclosed the investment value, stake size or a closing timetable, and Doctolib says NVIDIA will not receive a board seat.
AI moves into the clinical workflow
Doctolib is building its AI products inside the software healthcare professionals already use for consultations and administration. The company says its consultation assistant has documented more than 12 million patient visits and runs on a speech-recognition model developed by its own teams for medical vocabulary and several languages. It also describes assistants for coding, billing, secretarial work and document management, while clinical-decision support remains in development.
That installed workflow is commercially important. A standalone clinical AI tool has to win distribution and integrate with the systems around each consultation. Doctolib can instead introduce assistants alongside scheduling and practice-management functions already used by clinicians. The opportunity is to turn time saved on documentation and administration into deeper product use across a healthcare organisation; the execution test is whether the assistants remain accurate, trusted and useful enough to become routine rather than optional.
Compute is only one dependency
Doctolib says NVIDIA’s involvement will combine capital with access to AI expertise, chips, computing capacity and open software. The company plans to use that support to train proprietary models in Europe and accelerate a personal health assistant for patients as well as administrative and clinical assistants for professionals.
The partnership links a major healthcare distribution platform with an infrastructure supplier that benefits when more AI workloads reach production. For Doctolib, faster model training can shorten development cycles, but compute alone will not determine adoption. Healthcare professionals will judge the products by how well they fit existing work, reduce administrative effort and support care without adding new review burdens. The planned investment therefore backs both a technical programme and a deployment challenge: converting model capability into repeatable, trusted use across clinical workflows.
